To evaluate the methods and collection techniques currently used in stem cell mobilization for patients undergoing autologous transplantation.
DATA SOURCES
Literature search was performed through PubMed (1948-August 2009) and MEDLINE (1977-August 2009). Reference citations from publications identified were also reviewed.
STUDY SELECTION AND DATA EXTRACTION
All literature identified was reviewed for inclusion. Original research and retrospective cohorts, along with previously published systematic reviews of stem cell mobilization and growth factors, were evaluated. Abstract data on plerixafor were also reviewed.
DATA SYNTHESIS
Successful mobilization of an adequate number of progenitor cells can help ensure and improve time to neutrophil and platelet engraftment. A variety of methods have been studied to find the safest and most predictable mobilization of CD34+ progenitor cells, including use of single agents or the combinations of hematopoietic growth factors, chemotherapy, and a novel chemokine receptor 4 antagonist. Currently, granulocyte colony-stimulating factor (G-CSF) 10 Mg/kg daily started 4 days prior to apheresis remains the standard of care for initial mobilization therapy. In patients who fail to mobilize or who are at high risk for mobilization failure, cyclophosphamide in conjunction with G-CSF may be used. Plerixafor, a novel chemokine receptor antagonist, in combination with G-CSF has demonstrated superiority for achieving collection goals compared to G-CSF alone in 2 Phase 3 trials.
CONCLUSIONS
The optimal mobilization strategy is still unknown; however, colony-stimulating factors remain the most commonly used mobilization agents. Currently, chemotherapy or plerixafor in combination with G-CSF is a reasonable option in heavily pretreated and hard-to-mobilize patients with non-Hodgkin's lymphoma and multiple myeloma.
. CopelanEA.Hematopoietic stem-cell transplantation. N Engl J Med2006;354:1813–26.
2.
. AttalMHarousseauJLStoppaAMA prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med1996;335:91–7.
3.
. PhilipTGuglielmiCHagenbeekAAutologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med1995;333:1540–5.
4.
. Stem Cell Trialists' Collaborative Group.Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol2005;23:5074–87.
5.
. ChamplinRESchmitzNHorowitzMMBlood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood2000;95:3702–9.
6.
. SchmitzNLinchDCDregerPRandomised trial of filgrastimmobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet1996;347:353–7.
7.
. NademaneeASniecinskiISchmidtGMHigh-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol1994;12:2176–86.
8.
. WeaverCHBucknerCDCurtisLHEconomic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. Bone Marrow Transplant2002;29:159–64.
9.
. SienaSSchiavoRPedrazzoliPCarlo-StellaC.Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol2000;18:1360–77.
10.
. WeissmanIL.Stem cells: units of development, units of regeneration, and units in evolution. Cell2000;100:157–68.
11.
. LapidotTKolletO.The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia2002;16:1992–2003.
12.
. LapidotTPetitI.Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol2002;30:973–81.
13.
. TeixidoJHemlerMEGreenbergerJSAnklesariaP.Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest1992;90:358–67.
14.
. MohleRBautzFRafiiSMooreMABruggerWKanzL.The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood1998;91:4523–30.
15.
. AiutiAWebbIJBleulCSpringerTGutierrez-RamosJC.The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med1997;185:111–20.
16.
. LevesqueJPHendyJTakamatsuYSimmonsPJBendallLJ.Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest2003;111:187–96.
17.
. LevesqueJPHendyJTakamatsuYWilliamsBWinklerIGSimmonsPJ.Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol2002;30:440–9.
18.
. LevesqueJPTakamatsuYNilssonSKHaylockDNSimmonsPJ.Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood2001;98:1289–97.
19.
. StiffPJ.Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant1999;23 suppl 2:S29–33.
20.
. HaasRMohleRFruhaufSPatient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood1994;83:3787–94.
21.
. KessingerASharpJG.The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant2003;31:319–29.
22.
. MoskowitzCHGlassmanJRWuestDFactors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res1998;4:311–6.
23.
. KettererNSallesGMoulletIFactors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol1998;103:235–42.
24.
. NebenSHellmanSMontgomeryMFerraraJMauchP.Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol1993;21:156–62.
25.
. DregerPKlossMPetersenBAutologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood1995;86:3970–8.
26.
. KumarSDispenzieriALacyMQImpact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia2007;21:2035–42.
27.
. MazumderAKaufmanJNiesvizkyRLonialSVesoleDJagannathS.Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients (letter). Leukemia2008;22:1280–1; author reply 1–2.
28.
. BensingerWILonginKAppelbaumFPeripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol1994;87:825–31.
29.
. MorrisCLSiegelEBarlogieBMobilization of CD34+ cells in elderly patients (≥70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol2003;120:413–23.
30.
. PopatUSalibaRThandiRImpairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant2009;15:718–23.
31.
. ParipatiHStewartAKCabouSCompromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia2008;22:1282–4.
32.
. BensingerWAppelbaumFRowleySFactors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol1995;13:2547–55.
33.
. WattsMJSullivanAMJamiesonEProgenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol1997;15:535–46.
34.
. SchotsRVan RietIDamiaensSThe absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant1996;17:509–15.
35.
. SchwellaNBeyerJSchwanerIImpact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol1996;14:1114–21.
36.
. FordCDChanKJReillyWFPetersenFB.An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion2003;43:622–5.
37.
. MoncadaVBolanCYauYYLeitmanSF.Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion2003;43:495–501.
38.
. Cottler-FoxMHLapidotTPetitIStem cell mobilization. Hematology American Society of Hematology Education Program, Washington, DC, 2003:419–37.
39.
. AnderliniPPrzepiorkaDHuhYDuration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol1996;93:940–2.
. KaushanskyK.Lineage-specific hematopoietic growth factors. N Engl J Med2006;354:2034–45.
43.
. WinterJNLazarusHMRademakerAPhase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol1996;14:277–86.
44.
. NarayanasamiUKantetiRMorelliJRandomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood2001;98:2059–64.
45.
. SpitzerGAdkinsDMathewsMRandomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant1997;20:921–30.
46.
. AlegreATomasJFMartinez-ChamorroCComparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant1997;20:211–7.
47.
. DazziCCarielloARostiGIs there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?Leuk Lymphoma2000;39:301–10.
48.
. GianniAMSienaSBregniMGranulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet1989;2:580–5.
49.
. GazittYFreytesCOCallanderNSuccessful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother1999;8:173–83.
50.
. DemirerTAyliMOzcanMMobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol2002;116:468–74.
51.
. WeaverCHSchulmanKAWilson-RelyeaBBirchRWestWBucknerCD.Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol2000;18:43–53.
52.
. SchillerGVescioRFreytesCTransplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood1995;86:390–7.
53.
. MoskowitzCHBertinoJRGlassmanJRIfosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol1999;17:3776–85.
54.
. PavoneVGaudioFGuariniAMobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant2002;29:285–90.
55.
. AkhtarSTbakhiAHumaidanHEl WeshiARahalMMaghfoorI.ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant2006;37:277–82.
56.
. LeeJLKimSKimSWESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant2005;35:449–54.
57.
. HolowieckiJWojciechowskaMGiebelSIfosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients. Transplant Proc2000;32:1412–5.
58.
. ReiserMJostingADraubeASuccessful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant1999;23:1223–8.
59.
. AshiharaEShimazakiCOkanoAHatsuseMInabaTNakagawaM.Feasibility and efficacy of high-dose etoposide followed by low-dose G-CSF as a mobilization regimen in patients with non-Hodgkin's lymphoma. Haematologica2000;85:1112–4.
60.
. StewartDAGuoDMorrisDSuperior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant1999;23:111–7.
61.
. WeaverCHHazeltonBBirchRAn analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood1995;86:3961–9.
62.
. Gomez-EspuchJMoraledaJMOrtunoFMobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF. Bone Marrow Transplant2000;25:231–5.
63.
. OlivieriAOffidaniMCinieroLDHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant1995; 16:85–93.
64.
. DesikanKRBarlogieBJagannathSComparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol1998;16:1547–53.
65.
. GazittYCallanderNFreytesCOPeripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res2000;9:737–48.
66.
. MiloneGLeottaSIndelicatoFG-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplant2003;31:747–54.
67.
. PusicIJiangSYLanduaSImpact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant2008;14:1045–56.
68.
. HendrixCWFlexnerCMacFarlandRTPharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother2000;44: 1667–73.
69.
. De ClercqE.The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol2009;77:1655–64.
. StewartDASmithCMacFarlandRCalandraG.Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant2009;15:39–46.
72.
. FlomenbergNDevineSMDipersioJFThe use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood2005;106:1867–74.
73.
. CalandraGMcCartyJMcGuirkJAMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant2008;41:331–8.
74.
. CashenALopezSGaoFA Phase II Study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant2008;14:1253–61.
75.
. DiPersioJFMicallefINStiffPJPhase III, prospective, randomized, double-blind, placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol2009;27:4767–73.
76.
. DiPersioJ SEStadtmauerEANademaneeAPPlerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720–6.
77.
. StiffPMicallefIMccCarthyPTreatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant2009;15:249–56.
78.
. FowlerCJDunnAHayes-LattinBRescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant2009;43:909–17.
79.
. MicallefINStiffPJDiPersioJF.Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant2009;15:1578–86.
